ArticleJournal of virology1995
Pattern of disease after murine hepatitis virus strain 3 infection correlates with macrophage activation and not viral replication.
Article in Journal of virology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Pyrroloquinoline quinone protects against murine hepatitis virus strain 3-induced fulminant hepatitis by inhibiting the Keap1/Nrf2 signaling.Cytotechnology · 2024Article
- Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis.Cell death & disease · 2019Article
- VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism.Nature communications · 2017Article
- Toll-like receptor-2 exacerbates murine acute viral hepatitis.Immunology · 2016Article
- The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.International reviews of immunology · 2016Review
- Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis.Journal of virology · 2014Article
- Physiological functions and clinical implications of fibrinogen-like 2: A review.World journal of clinical infectious diseases · 2013Article
- Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection.PLoS pathogens · 2011Article
- The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection.Rambam Maimonides medical journal · 2010Article
- Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection.Virology journal · 2007Article
- Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity.Hepatology (Baltimore, Md.) · 2006Article
- Immunopathogenesis of coronavirus infections: implications for SARS.Nature reviews. Immunology · 2005Review
- Severe acute respiratory syndrome and the liver.Hepatology (Baltimore, Md.) · 2004Review
- Antibody responsiveness during immunization and challenge of genetically modified antibody responder mice with murine hepatitis virus 3.Immunobiology · 2003Article
- Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis.The American journal of pathology · 2000Article
- Coronavirus MHV-3-induced apoptosis in macrophages.Virology · 1998Article
- Resistance to murine hepatitis virus strain 3 is dependent on production of nitric oxide.Journal of virology · 1998Article
- Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection.Journal of virology · 1997Article
- Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.Journal of virology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Murine hepatitis virus strain (MHV-3) produces a strain-dependent pattern of disease which has been used as a model for fulminant viral hepatitis. This study was undertaken to examine whether there was a correlation between macrophage activation and susceptibility or resistance to MHV-3 infection. Peritoneal macrophages were isolated from resistant A/J and susceptible BALB/cJ mice and, following stimulation with MHV-3 or lipopolysaccharide (LPS), analyzed for transcription of mRNA and production of interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta), mouse fibrinogen-like protein (musfiblp), tissue factor (TF), leukotriene B4, and prostaglandin E2 (PGE2). Macrophages from BALB/cJ mice produced greater amounts of IL-1, TNF-alpha, TGF-beta, leukotriene B4, and musfiblp following MHV-3 infection than macrophages from resistant A/J mice, whereas in response to LPS, equivalent amounts of IL-1, TNF-alpha, TGF-beta, and TF were produced by macrophages from both strains of mice. Levels of mRNA of IL-1, TNF-alpha, and musfiblp were greater and more persistent in BALB/cJ than in A/J macrophages, whereas the levels and kinetics of IL-1, TNF-alpha, and TF mRNA following LPS stimulation were identical in macrophages from both strains of mice. Levels of production of PGE2 by MHV-3-stimulated macrophages from resistant and susceptible mice were equivalent; however, the time course for induction of PGE2, differed, but the total quantity of PGE2 produced was insufficient to inhibit induction of musfiblp, a procoagulant known to correlate with development of fulminant hepatic necrosis in susceptible mice. These results demonstrate marked differences in production of inflammatory mediators to MHV-3 infection in macrophages from resistant A/J and susceptible BALB/cJ mice, which may explain the marked hepatic necrosis and fibrin deposition and account for the lethality of MHV-3 in susceptible mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.